Thansinee Ounhasuttiyanon, MD¹, Thep Chalermchai, MD, PhD¹, Vitoon Jularattanaporn, MD, PhD¹

Background: Psoriasis is a chronic inflammatory skin disease. Clinical manifestation with arterial stiffness (AS), atherosclerosis, metabolic syndrome, and cardiovascular diseases are common in psoriasis.

Objective: To compare AS evaluated by cardio-ankle vascular index (CAVI), clinical and laboratory cardiovascular parameters between psoriasis and non-psoriasis subjects.

Materials and Methods: A prospective, observational, analytic study enrolled 26 plaque psoriasis and 104 non-psoriasis participants as the controls, for a one-to-four ratio, at Mae Fah Luang Hospital, Bangkok, Thailand. AS measured by CAVI, clinical, and laboratory evaluation for cardiovascular risk factors were measured and determined between the two groups.

Results: The prevalent rate of arterials stiffness or CAVI greater than 8.0 in plaque psoriasis group was 73.1%, which is significantly higher than non-psoriasis subjects of 20.2% (p<0.001). Furthermore, those patients with psoriasis had a significantly higher percentage of those aged older than 40, fasting glucose greater than 100 mg/dL, triglyceride greater than 150 mg/dL, and LDL-cholesterol greater than 130 mg/dL than non-psoriasis group (p<0.05). Nevertheless, CAVI greater than 8.0 or AS was an only independent factor associated with plaque psoriasis after adjusting any other factors, with an adjusted odds ratio of 10.73 and a 95% confidence interval of 3.98 to 28.87 (p<0.001).

Conclusion: The patients with plaque psoriasis were 10.73 times significantly greater to predict CAVI greater than 8.0 or AS than non-psoriatic group. To prevent cardiovascular events and further long-term complications, early cardiovascular screening with CAVI in psoriasis patients is an optional evaluation tool.

Received 30 June 2025 | Revised 4 December 2025 | Accepted 8 December 2025

DOI: 10.35755/jmedassocthai.2026.1.03224